AACR Meeting Presentations
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI): new translational data from the Phase 1b trial of CMP-001 in subjects with advanced melanoma (Sunday)
Blueprint Medicines Corporation (NASDAQ: BPMC): interim analysis of Phase 2 data for avapritinib in patients with advanced systemic mastocytosis (Sunday)
Mirati Therapeutics, Inc. (NASDAQ: MRTX) and
BeiGene, Ltd. (NASDAQ: BGNE): Phase 1b safety/tolerability and preliminary antitumor activity data for Mirati s sitravatinib plus BeiGene s tislelizumab in patients with advanced platinum-resistant ovarian cancer as well as patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma (Sunday)
Beigene: results from the Phase 3 study of tislelizumab versus docetaxel as second or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (Monday)
Press release content from Business Wire. The AP news staff was not involved in its creation.
New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio
April 8, 2021 GMT
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Apr 8, 2021
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Genentech neuroscience portfolio across six therapeutic areas, including Evrysdi™ (risdiplam) for spinal muscular atrophy (SMA), Ocrevus ® (ocrelizumab) in relapsing and primary progressive multiple sclerosis (RMS and PPMS), investigational Bruton’s tyrosine kinase inhibitor (BTKi) fenebrutinib in Phase III trials for RMS and PPMS, Enspryng™ (sat
What does your brain do when you sleep? And more importantly, how does one achieve an optimal quality of sleep? New Canaan Library is pleased to welcome Dr. Daniel Barone, Associate Medical Director of the Weill Cornell Center for Sleep Medicine, on Tuesday, April 13 at 7 PM EST. Dr. Barone will cover numerous aspects of sleep health and our brains, including a review of several sleep disorders like insomnia and sleep apnea, and various treatment for those disorders. Register for this information-packed lecture with Dr. Daniel Barone and learn how to stay healthy and snooze effectively.
Zoom sign in information will be provided upon registration at newcanaanlibrary.org.
(0)
EVRYSDI 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA)
OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS)
Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs)
Data for investigational MS medicine fenebrutinib support its safety profile and high potency
Additional presentations on investigational programmes, including Alzheimer s disease and Huntington s disease, help advance scientific understanding of neurological disorders
Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually Apr
Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology s 73rd 2021 Virtual Meeting
News provided by
Share this article
Share this article
SAN DIEGO, April 8, 2021 /PRNewswire/ Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academy of Neurology s (AAN) 73rd Annual Meeting being held virtually from April 17–22, 2021.
Key highlights include:
Analysis from the KINECT 4 Phase III open-label study that demonstrated the effect of INGREZZA
® (valbenazine) capsules on the overall severity of abnormal movements in adult patients living with tardive dyskinesia based on item 8 of the abnormal involuntary movement scale (AIMS)